Pulmonary Function Testing System Market Size, Share & COVID-19 Impact Analysis, By Type (Portable PFT Systems, and Complete PFT Systems), By End-user (Hospitals, Physical Examination (Diagnostic) Centers, Physician Groups (Clinics), and Others), and Regional Forecast, 2022-2029

The global pulmonary function testing system market size was valued at USD 136.6 million in 2021. The market is projected to grow from USD 141.8 million in 2022 to USD 190.2 million by 2029, exhibiting a CAGR of 4.3% during the forecast period. The global COVID-19 pandemic has been unprecedented and staggering, with pulmonary function testing systems experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. Based on our analysis, the pulmonary function testing system market exhibited a slower growth of 1.4% in 2020 as compared to 2019.

Pulmonary function testing system is a device that performs various pulmonary function tests such as respiratory mechanics, nitrogen washout, spirometry, lung volumes, vital capacity, plethysmography, and diffusion capacity. There are two types of devices available namely complete, and portable systems. These devices can be utilized to monitor people suffering from severe breathing complaints such as asthma and COPD.

The pulmonary function testing system market growth is attributed to the growing occurrence of chronic respiratory ailments. Furthermore, technological progressions, such as portable systems are anticipated to increase the demand for these devices in the coming years. Additionally, rising awareness regarding the usage of these devices and increasing product launches by the companies are predicted to increase the market growth during the forecast timeframe.

COVID-19 IMPACT

COVID-19 Pandemic Slowed Market Growth in 2020 due to Shutdown of Pulmonary Clinics

The influence of COVID-19 resulted in lesser demand for pulmonary function testing systems during the market analysis period. This is attributed to the substantial decrease in the implementation of systems for testing pulmonary function during the peak time of COVID-19. However, after the relaxation of lockdown in some countries, the PFT resumed in healthcare facilities with the RT-PCR test. The global market witnessed a slow growth rate of 1.4% in 2020 as compared to 3.3% in 2019.

The widespread disruption caused by COVID-19 has significantly affected the manufacturing of these systems. The imposition of lockdown in potentially affected areas has led to a halt in the supply chain of portable systems leading to a decrease in sales. However, at the end of 2020, testing centers and clinics were resumed, contributing to the market's substantial growth in 2021.

Furthermore, multiple organizations, such as the Canadian Thoracic Society, European Thoracic Society, and the American Thoracic Society, issued guidelines to be followed amid the COVID-19 outbreak while resuming services. This increased the number of patients testing pulmonary function and also increased the demand for these systems from various healthcare facilities.

• According to the research study published by the Canadian Thoracic Society (CTS) in August 2020, during the COVID-19 pandemic, testing for pulmonary function was resumed only for those patients whose COVID-19 tests were negative. Such guidelines favored the resumption of testing during COVID-19.

LATEST TRENDS

Request a Free sample to learn more about this report.

Shift towards Portable Systems from Complete Systems to Thrive Market Growth

The companies functioning in the global market incessantly emphasize on developments, such as launching portable systems with more parameters and promoting the adoption of these devices in independent clinics. These strategies shifted the adoption of complete to portable systems, thereby spurring the overall market growth.

Aspects such as immobile, low cost, and presence of standard parameters, such as lung volumes, diffusion capacity, and spirometry, stimulated the healthcare facilities to shift towards portable systems. Moreover, many market players are developing new portable systems to diagnose various chronic respiratory disorders, which is anticipated to drive market growth during the forecast period.

DRIVING FACTORS

Increasing Prevalence of Respiratory Diseases to Drive Market

In recent years, respiratory ailments, such as Chronic Obstructive Pulmonary Disease (COPD), asthma, lung cancer, and occupational lung diseases, have been the leading reasons of fatality across the globe. Furthermore, there is a considerable increase in the incidence of chronic obstructive pulmonary diseases and asthma globally, especially in developing countries.

• According to the Global Asthma Report 2018, in India, among 1.31 billion people, about 2% of adults and 6% of children have asthma. Such high cases of asthma are expected to increase the adoption of these systems during the forecast timeframe.

In COPD and other chronic respiratory diseases, lung capacity is an important parameter. Lung capacity refers to the air volume in lungs at different respiratory cycle phases. The pulmonary function testing systems help to measure different parameters of the lungs with the help of various tests such as spirometry and plethysmography and diagnose COPD and other lung-related disorders.

Such a huge occurrence of chronic respiratory diseases necessitating pulmonary function tests and the rising focus of companies to increase their presence in developing countries for these systems are expected to boost the market growth in the coming years

Rising Awareness of Early Diagnosis and Advancements of Testing Systems to Propel the Market

Pulmonary function tests are non-invasive tests that analyze the functioning of the lungs. The tests measure capacity, lung volume, gas exchange, and flow rates and determine the treatment for certain lung disorders.

PFTs are very useful in identifying the early-stage abnormalities in asymptomatic patients and in evaluating the damage to the lungs before any signs and symptoms develop. Due to these reasons, pulmonary function testing has become important among physicians for screening and detection of pulmonary disorders.

• For instance, a study published by the American Journal of Managed Care (AJMC) in May 2021 concluded that physicians should diagnose using pulmonary function tests to ensure that patients are appropriately diagnosed with COPD. Such studies favor the usage of systems for lung testing, thereby increasing their adoption during the forecast period.

Furthermore, the increasing diagnosis of lung function from pulmonary function tests have stimulated companies to introduce advanced testing systems in the market. The advanced product’s clearance by the U.S. FDA in the market is expected to increase its adoption among healthcare providers, especially in independent physician clinics.

• For instance, in August 2019, VYAIRE MEDICAL, INC. announced the 510(k) clearance by the U.S. FDA for its two PFT technologies, which are Vyntus ONE and Vyntus BODY with SentrySuite Software.

The advancement of newly launched testing devices coupled with increasing awareness of devices among healthcare providers is expected to propel the market in the long run.

RESTRAINING FACTORS

Risk of Cross Contamination and Lack of Skilled Healthcare Professionals in Underdeveloped Countries Hamper Market Growth

Pulmonary function testing represents a potential avenue for the transmission of infection due to the congregation of patients with lung disease and the potential for coughing and droplet formation surrounding pulmonary function test procedures.

These systems include mouthpieces, rebreathing valves, and tubings used in the laboratory. Mouthpieces are the most common cause of cross-infection during testing.

Factors, such as exposed surface areas, quality of upholstery, general clutter, air conditioning, optimum temperature, and humidity conditions, lead to the cross-infection such as the risk of the development of tuberculosis.

Furthermore, the complexity of these systems, which measures various parameters in diagnosing lung volume capacity requires skilled physicians and technicians. However, there is a shortage of trained healthcare professionals in developing countries.

• For instance, according to the article published by BMJ Publishing Group Ltd in May 2019, in India, the density of the total health professional is estimated to be 29 per 10,000 populations; however, only 16 per 10,000 is the density of trained workers. Furthermore, the trained health workforce in India does not meet the minimum threshold of 22.8 skilled workers per 10,000 populations, which is recommended by the World Health Organization (WHO).

Such unavailability of a skilled workforce to operate PFT systems and the high risk of contamination associated with these systems are expected to hamper the market growth during the forecast period.

SEGMENTATION

By Type Analysis

To know how our report can help streamline your business, Speak to Analyst

Complete PFT Systems Segment to Hold a Prime Share due to the Growing Adoption in Hospitals

Based on type, the market is segmented into portable PFT systems and complete PFT systems

In 2021, the complete PFT systems segment held the highest pulmonary function testing system market share and was predicted to extend at a significant CAGR during the forecast period, 2022-2029. An increase in the number of hospitals requiring complete systems is expected to drive segmental growth. Moreover, the surging number of patient visits coupled with the huge occurrence of respiratory illness, such as asthma and COPD, are expected to increase the demand for complete systems.

• For instance, according to the National Ambulatory Medical Care Survey: 2018 published by CDC, the percentage of visits to office-based physicians with COPD indicated was 4.1% of the total physician office visits, and patient visits to the emergency department with COPD was 873,000. Such an increase in the visits to healthcare facilities is expected to increase the segmental growth during the forecast period.

The portable PFT systems segment is projected to expand at the highest CAGR during the forecast timeframe. The high growth rate of this segment is due to the increase in the adoption of portable systems in independent and diagnostics clinics. Moreover, factors such as increasing launches of these products for the diagnosis of asthma and COPD and rising air pollution are expected to surge its demand in the future.

By End-user Analysis

Hospitals Segment to Continue Dominance Due to Rising Patient Visits

Based on end-user, the market is segmented into hospitals, physical examination (diagnostic) centers, physician groups (clinics), and others.

The hospitals segment held the largest market share and is expected to expand at a moderate CAGR during the forecast period. The segmental growth is due to the surging footfalls of asthma and COPD patients in the hospitals. Moreover, the growing adoption of complete systems for diagnosing patients in hospitals is expected to drive the segment's growth in the coming years.

The physician groups (clinics) segment is projected to expand at the highest CAGR during the forecast timeframe. The segmental growth is attributed to factors such as the growing incidence of chronic respiratory diseases, rising focus of key players in the market on introducing portable systems for clinics, and an increase in the implementation of these systems in clinics.

• For instance, in August 2019, Ruby Hall in Pune, India announced the installation of a pulmonary function test machine, Vyntus Body, which is manufactured by CareFusion. The hospital stated that the machine helps generate accurate lung disease tests.

Such introduction of these systems in the physician groups (clinics) pooled with the increasing number of COPD and asthma patients in clinics is expected to boost the segmental growth during the forecast period.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The North America market was valued at USD 57.0 million in 2021 and is projected to expand at a substantial CAGR during the forecast period. The growth is due to the prompt implementation of portable systems and the bolstering usage of these devices in physician groups (clinics) in the region. Furthermore, an increasing prevalence of chronic respiratory diseases and rising hospital admissions are anticipated to propel the market growth across the region.

Europe is projected to expand at a reasonable CAGR during the forecast timeframe. The growth is due to the surging number of patients suffering from COPD and asthma and the growing number of visits to independent physician clinics to diagnose these diseases. Furthermore, the improvement in healthcare infrastructure and the presence of major players in this region surge the demand for PFT systems in the region.

The market in Asia Pacific is projected to grow at the largest CAGR during the forecast period. The market growth across the region is accredited to the growing awareness regarding the usage of pulmonary function tests and increasing emphasis on enhancing hospital infrastructure. Furthermore, the rising footprints of market players in developing countries of Asia Pacific are expected to propel the market during the forecast period.

The market in Latin America and the Middle East & Africa is anticipated to expand at a lower CAGR compared to other regions during the forecast period. The growth is attributed to the rising investments in healthcare improvement, increasing prevalence of COPD and asthma, and growing demand for diagnosing lung function across these regions.

KEY INDUSTRY PLAYERS

Strong Product Portfolio of Companies to Strengthen their Market Position

The market is consolidated due to large market shares accounted for by key companies operating in the market.

VYAIRE MEDICAL, INC. and MGC Diagnostics Corporation accounted for the highest market share of the market. The large shares of these companies are due to their strong product portfolio of PFT systems and increasing focus on the approvals to introduce advanced devices in the market.

Moreover, the consistent focus of the key companies on introducing these systems in developing countries is expected to strengthen their market shares during the forecast period. Furthermore, companies, such as PulmOne Advanced Medical Devices, have been aggressively focusing on expanding their products and geographical presence worldwide.

Other companies with new product launches include ndd Medizintechnik AG, KoKo PFT, CHEST M.I., Inc., and other small & medium-sized market players. Moreover, a growing focus of companies on collaboration with healthcare providers is expected to fuel the global market growth in the coming years.

LIST OF KEY COMPANIES PROFILED:

• ndd Medizintechnik AG (Switzerland)


• COSMED srl (Italy)


• MGC Diagnostics Corporation (U.S.)


• PulmOne Advanced Medical Devices (Israel)


• CHEST M.I., Inc. (Japan)


• VYAIRE MEDICAL, INC. (U.S.)


• KoKo PFT (U.S.)


• Medical Electronic Construction (Belgium)

KEY INDUSTRY DEVELOPMENTS:

• June 2022: PulmOne Advanced Medical Devices announced the opening of a new subsidiary, PulmOne France.


• March 2022: KoKo PFT signed a three-year partnership with MAGNET GROUP. The partnership gives access to all respiratory and pulmonary function testing systems of the company.


• September 2020: PulmOne Advanced Medical Devices announced the launch of MiniBox Academy, an innovative, self-paced e-learning training and certification program for MiniBox+ customers. The academy is designed to improve PFT testing expertise, ensure testing consistency, reproducibility, and accuracy and facilitate an outstanding patient experience.


• November 2019: PulmOne Advanced Medical Devices entered into a partnership with Circassia Pharmaceuticals to develop NIOX VERO as an integrated add-on to PulmOne's MiniBox+.


• May 2017: Medical Electronic Construction announced that the company had become the distributor of THORASYS for its complete products in Belgium.

REPORT COVERAGE

An Infographic Representation of Pulmonary Function Testing Systems Market

View Full Infographic

To get information on various segments, share your queries with us

The market research report provides a detailed competitive landscape and market dynamics. It focuses on key aspects, such as regulatory policies regarding the prevalence of major pulmonary diseases, such as COPD and asthma. Furthermore, the report provides information related to key industry developments such as mergers and acquisitions. In addition, the report includes insights related to industry trends and the impact of COVID-19 on the market.

Report Scope & Segmentation